D. Ricard, A. Idbaih, F. Ducray, M. Lahutte, K. Hoang-xuan et al., Primary brain tumours in adults, Lancet, vol.379, issue.11, pp.61346-61355, 2012.

D. N. Louis, A. Perry, G. Reifenberger, A. Von-deimling, D. Figarella-branger et al., The 2016 World Health Organization classification of tumors of the central nervous system: a summary, Acta Neuropathol, vol.131, pp.803-823, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01479018

L. M. Deangelis, Brain tumors, N Engl J Med, vol.344, pp.114-137, 2001.

R. Stupp, M. Brada, M. J. Bent, . Van-den, J. C. Tonn et al., Highgrade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.25, pp.93-101, 2014.

R. Stupp, M. E. Hegi, W. P. Mason, M. J. Van-den-bent, M. Taphoorn et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol, vol.10, pp.459-66, 2009.

R. Stupp, W. P. Mason, M. J. Van-den-bent, M. Weller, B. Fisher et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, vol.352, pp.987-96, 2005.

M. D. Walker, S. B. Green, D. P. Byar, E. J. Alexander, U. Batzdorf et al., Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery, N Engl J Med, vol.303, pp.1323-1352, 1980.

M. D. Walker, T. A. Strike, and G. E. Sheline, An analysis of dose-effect relationship in the radiotherapy of malignant gliomas, Int J Radiat Oncol Biol Phys, vol.5, pp.1725-1756, 1979.

N. M. Bleehen and S. P. Stenning, A medical research council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party, Br J Cancer, vol.64, pp.769-774, 1991.

J. Biau, E. Chautard, D. Koning, L. Court, F. Pereira et al., Predictive biomarkers of resistance to hypofractionated radiotherapy in high grade glioma, Radiat Oncol, vol.12, p.123, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01643040

N. Khan, M. K. Khan, A. Almasan, A. D. Singh, and R. Macklis, The evolving role of radiation therapy in the management of malignant melanoma, Int J Radiat Oncol Biol Phys, vol.80, pp.645-54, 2011.

G. Stevens and M. J. Mckay, Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma, Lancet Oncol, vol.7, pp.575-83, 2006.

J. F. Ward, DNA damage and repair, Basic Life Sci, vol.58, pp.403-418, 1991.

W. Burkart, T. Jung, and G. Frasch, Damage pattern as a function of radiation quality and other factors, C R Acad Sci III, Sci Vie, vol.322, pp.89-101, 1999.

I. R. Radford, The level of induced DNA double-strand breakage correlates with cell killing after X-irradiation, Int J Radiat Biol Relat Stud Phys Chem Med, vol.48, pp.45-54, 1985.

P. A. Bradbury and M. R. Middleton, DNA repair pathways in drug resistance in melanoma, vol.15, pp.421-426, 2004.

C. Wang and S. P. Lees-miller, Detection and repair of ionizing radiationinduced DNA double strand breaks: new developments in nonhomologous end joining, Int J Radiat Oncol Biol Phys, vol.86, pp.440-449, 2013.

J. Biau, F. Devun, W. Jdey, E. Kotula, M. Quanz et al., A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma, Neoplasia, vol.16, pp.835-879, 2014.

T. Helleday, E. Petermann, C. Lundin, B. Hodgson, and R. A. Sharma, DNA repair pathways as targets for cancer therapy, Nat Rev Cancer, vol.8, pp.193-204, 2008.

M. Quanz, D. Chassoux, N. Berthault, C. Agrario, J. S. Sun et al., Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response, PLoS ONE, vol.4, p.6298, 2009.

M. Quanz, N. Berthault, C. Roulin, M. Roy, A. Herbette et al., Small-molecule drugs mimicking DNA damage: a new strategy for sensitizing tumors to radiotherapy, Clin Cancer Res, vol.15, pp.1308-1324, 2009.

N. Coquery, N. Pannetier, R. Farion, A. Herbette, L. Azurmendi et al., Distribution and radiosensitizing effect of cholesterol-coupled dbait molecule in rat model of glioblastoma, PLoS ONE, vol.7, p.40567, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00874418

L. Tourneau, C. Dreno, B. Kirova, Y. Grob, J. J. Jouary et al., Firstin-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma, Br J Cancer, vol.114, pp.1199-205, 2016.

D. F. Hayes, Biomarker validation and testing, Mol Oncol, vol.9, pp.960-966, 2015.

J. Biau, E. Chautard, F. Court, B. Pereira, P. Verrelle et al., Global conservation of protein status between cell lines and xenografts, Transl Oncol, vol.9, pp.313-321, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01643043

N. L. Henry and D. F. Hayes, Cancer biomarkers, Mol Oncol, vol.6, pp.140-146, 2012.

R. I. Gallagher and V. Espina, Reverse phase protein arrays: mapping the path towards personalized medicine, Mol Diagn Ther, vol.18, pp.619-630, 2014.

M. Masuda and T. Yamada, Signaling pathway profiling by reverse-phase protein array for personalized cancer medicine, Biochim Biophys Acta, vol.1854, pp.651-658, 2015.

R. Akbani, K. F. Becker, N. Carragher, T. Goldstein, L. De-koning et al., Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society, Mol Cell Proteom, vol.13, pp.1625-1668, 2014.

M. Quanz, A. Herbette, M. Sayarath, L. De-koning, T. Dubois et al., Heat shock protein 90? (Hsp90?) is phosphorylated in response to DNA damage and accumulates in repair foci, J Biol Chem, vol.287, pp.8803-8818, 2012.

S. Troncale, A. Barbet, L. Coulibaly, E. Henry, B. He et al., NormaCurve: a SuperCurve-based method that simultaneously quantifies and normalizes reverse phase protein array data, PLoS ONE, vol.7, p.38686, 2012.

D. Vordermark, O. Kölbl, K. Ruprecht, G. H. Vince, K. Bratengeier et al., Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma, BMC Cancer, vol.5, p.55, 2005.

Y. Zhu, J. Hu, Y. Hu, and W. Liu, Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance, Cancer Treat Rev, vol.35, pp.590-596, 2009.

C. J. Lord and A. Ashworth, The DNA damage response and cancer therapy, Nature, vol.481, pp.287-94, 2012.

A. J. Chalmers, M. Lakshman, N. Chan, and R. G. Bristow, Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets, Semin Radiat Oncol, vol.20, pp.274-81, 2010.

J. N. Sarkaria, Identifying inhibitors of ATM and ATR kinase activities, Methods Mol Med, vol.85, pp.49-56, 2003.

E. T. Shinohara, L. Geng, J. Tan, H. Chen, Y. Shir et al., DNAdependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs, Cancer Res, vol.65, pp.4987-92, 2005.

A. Kashishian, H. Douangpanya, D. Clark, S. T. Schlachter, C. T. Eary et al., DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer, Mol Cancer Ther, vol.2, pp.1257-64, 2003.

U. Raju, O. Riesterer, Z. Q. Wang, D. P. Molkentine, J. M. Molkentine et al., Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways, Radiother Oncol, vol.105, pp.241-249, 2012.

A. Croset, F. P. Cordelières, N. Berthault, C. Buhler, J. S. Sun et al., Inhibition of DNA damage repair by artificial activation of PARP with siDNA, Nucleic Acids Res, vol.41, pp.7344-55, 2013.

J. T. Mckenzie, J. N. Guarnaschelli, A. S. Vagal, R. E. Warnick, and J. C. Breneman, Hypofractionated stereotactic radiotherapy for unifocal and multifocal recurrence of malignant gliomas, J Neurooncol, vol.113, pp.403-412, 2013.

G. Yazici, M. Cengiz, G. Ozyigit, G. Eren, F. Yildiz et al., Hypofractionated stereotactic reirradiation for recurrent glioblastoma, J Neurooncol, vol.120, pp.117-140, 2014.

T. Khalil, J. J. Lemaire, V. Dedieu, and D. Donnarieix, MRI tumor response and clinical outcomes after LINAC radiosurgery on 50 patients with recurrent malignant gliomas, J Radiosurg SBRT, vol.4, pp.291-305, 2013.

G. Noël and J. J. Mazeron, Cancer Radiother, vol.14, pp.421-458, 2010.

G. Noël, B. Ammar, C. N. Feuvret, L. Valery, C. A. Cornu et al.,

, Rev Neurol, vol.160, pp.539-545, 2004.

H. Brem, S. Piantadosi, P. C. Burger, M. Walker, R. Selker et al., Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group, Lancet, vol.345, pp.1008-1020, 1995.

G. Frosina, Advances in drug delivery to high grade gliomas, Brain Pathol, vol.26, pp.689-700, 2016.

A. Jahangiri, A. T. Chin, P. M. Flanigan, R. Chen, K. Bankiewicz et al., Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies, J Neurosurg, vol.126, pp.1-10, 2016.

M. Miyai, H. Tomita, A. Soeda, H. Yano, T. Iwama et al., Current trends in mouse models of glioblastoma, J Neurooncol, vol.135, pp.423-455, 2017.

T. P. Kegelman, B. Hu, L. Emdad, S. K. Das, D. Sarkar et al., In vivo modeling of malignant glioma: the road to effective therapy, Adv Cancer Res, vol.121, pp.261-330, 2014.

S. S. Stylli, R. B. Luwor, T. Ware, F. Tan, and A. H. Kaye, Mouse models of glioma, J Clin Neurosci, vol.22, pp.619-645, 2015.

M. R. Junttila and F. J. De-sauvage, Influence of tumour micro-environment heterogeneity on therapeutic response, Nature, vol.501, pp.346-54, 2013.

K. Roemer, Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators, Biol Chem, vol.380, pp.879-87, 1999.

K. Vermeulen, D. R. Van-bockstaele, and Z. N. Berneman, The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer, Cell Prolif, vol.36, pp.131-149, 2003.

A. Schlegel, C. Buhler, F. Devun, C. Agrario, S. Urien et al., Pharmacokinetics and toxicity in rats and monkeys of coDbait: a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol, Mol Ther Nucleic Acids, vol.1, p.33, 2012.

L. Thangue, N. B. Kerr, and D. J. , Predictive biomarkers: a paradigm shift towards personalized cancer medicine, Nat Rev Clin Oncol, vol.8, pp.587-96, 2011.

K. Komatsu, NBS1 and multiple regulations of DNA damage response, J Radiat Res, issue.1, pp.11-17, 2016.

V. Turinetto and C. Giachino, Multiple facets of histone variant H2AX: a DNA double-strand-break marker with several biological functions, Nucleic Acids Res, vol.43, pp.2489-2498, 2015.